Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 0 15 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 0 15 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE vs POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Potassium chloride provides potassium ions for cellular homeostasis, essential for nerve conduction, muscle contraction, and acid-base balance. Dextrose 5% provides a caloric source and may reduce protein catabolism. Sodium chloride 0.45% provides sodium and chloride ions to maintain extracellular fluid volume and osmolarity.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
IV infusion at a rate dependent on patient's fluid and electrolyte needs; typical adult maintenance: 1000-2000 mL/day, providing 20-40 mEq potassium per liter.
None Documented
None Documented
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateTerminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Potassium: terminal half-life approximately 12 hours (3-compartment model), but distribution phase ~1 hour; clinical context: steady-state reached in 2-3 days.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Potassium: primarily renal (>90%) via distal tubule secretion; minimal fecal. Chloride: renal reabsorption/excretion linked to sodium. Dextrose: metabolized to CO2 and water; <2% renal. Sodium: renal excretion regulated by aldosterone.
Category C
Category A/B
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."